In PBMCs from patients with Hashimoto's thyroiditis (HT) and controls, rosiglitazone reduced IFN-γ expression by CD4+ and CD8+ T lymphocytes in a dose-dependent manner, but the degree of inhibition was significantly greater in healthy subjects than patients with HT. The gene discussed is CD8A; the disease is hematocrit.